An innovative method of nonclinical efficacy and toxicological evaluation of recombinant Salmonella typhi Ty21a expressing HPV16 and 18 L1 proteins
Authors:
Open Access
Abstract
No abstract availableKeywords
Funding Information
- Department of Biotechnology, Ministry of Science and Technology, India
This publication has 5 references indexed in Scilit:
- Nonclinical safety evaluation of oral recombinant anti-human papilloma virus vaccine (RHPV 16 & 18): Regulatory toxicology studies in mice, rats and rabbits – An innovative approachVaccine, 2021
- Generation and characterization of neutralizing monoclonal antibodies against baculo-expressed HPV 16 VLPsEuropean Journal of Microbiology and Immunology, 2014
- Human papillomavirus vaccines: current issues & future.2009
- In Vivo Characterization of the Murine Intranasal Model for Assessing the Immunogenicity of AttenuatedSalmonella entericaSerovar Typhi Strains as Live Mucosal Vaccines and as Live VectorsInfection and Immunity, 2000
- Human papillomavirus type 16 virus-like particles expressed in attenuated Salmonella typhimurium elicit mucosal and systemic neutralizing antibodies in miceInfection and Immunity, 1997